Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin v. Lucentis: An Early Test Case For Medicare ACOs?

Executive Summary

Medicare costs for covering Genentech’s Lucentis for wet age-related macular degeneration will get heightened scrutiny now that a widely anticipated National Institutes of Health trial has confirmed that much-less-expensive treatment with the company’s Avastin is as effective.

You may also be interested in...



CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review

CMS’ Medicare Evidence Development and Coverage Advisory Committee is scheduled to meet Sept. 21 to consider whether use of anti-VEGF drugs, including Roche’s Avastin (bevacizumab) and Roche/Genentech’s Lucentis (ranibizumab), are “reasonable and necessary” for treatment of diabetic macular edema.

CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review

CMS’ Medicare Evidence Development and Coverage Advisory Committee is scheduled to meet Sept. 21 to consider whether use of anti-VEGF drugs, including Roche’s Avastin (bevacizumab) and Roche/Genentech’s Lucentis (ranibizumab), are “reasonable and necessary” for treatment of diabetic macular edema.

Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.

Related Content

Topics

UsernamePublicRestriction

Register

PS053369

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel